NASDAQ: ATHXAthersys Inc Stock
$0.33+0.03 (+10%)
Updated Sep 26, 2023
ATHX Price
$0.33
Fair Value Price
$0.50
Market Cap
$7.47M
52 Week Low
$0.26
52 Week High
$2.76
P/E
-0.12x
P/B
-0.2x
P/S
124.2x
PEG
N/A
Dividend Yield
N/A
Revenue
$145.00k
Earnings
-$47.41M
Gross Margin
100%
Operating Margin
-32,693.1%
Profit Margin
-32,693.1%
Debt to Equity
-1.28
Operating Cash Flow
-$33M
Beta
0.69
Next Earnings
Nov 13, 2023
Ex-Dividend
N/A
Next Dividend
N/A
ATHX Overview
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ATHX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATHX ($0.33) is undervalued by 33.95% relative to our estimate of its Fair Value price of $0.50 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ATHX ($0.33) is significantly undervalued by 33.95% relative to our estimate of its Fair Value price of $0.50 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ATHX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ATHX due diligence checks available for Premium users.
Be the first to know about important ATHX news, forecast changes, insider trades & much more!
ATHX News
Valuation
ATHX fair value
Fair Value of ATHX stock based on Discounted Cash Flow (DCF)
Price
$0.33
Fair Value
$0.50
Undervalued by
34.34%
ATHX ($0.33) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ATHX ($0.33) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ATHX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ATHX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
13.22x
Market
14.06x
ATHX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.2x
Industry
5.13x
ATHX's financial health
Profit margin
Revenue
$49.0k
Net Income
-$12.9M
Profit Margin
-26,375.5%
ATHX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ATHX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.5M
Liabilities
$47.9M
Debt to equity
-1.28
ATHX's short-term liabilities ($42.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATHX's long-term liabilities ($5.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATHX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATHX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.6M
Investing
$0.0
Financing
$3.3M
ATHX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ATHX vs Biotech Stocks
Athersys Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.